Novo said its next-generation obesity drug CagriSema led to an average 25% weight loss among women at 68 weeks in a new analysis following a late-stage trial, versus 3% with placebo. The result assumes all patients stayed on treatment without interruption, and Novo says further work is needed to confirm two post-study analyses. A separate analysis of about 1,900 women found weight loss of 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal women. The drug is expected to launch early next year, though investors have been lukewarm after earlier trial results fell short of expectations, and analysts forecast $11.84 billion in 2028 obesity sales per FactSet consensus.
Summary written by Upside AI from the original article. Read the source for full details.
Keywords
Novo Nordiskpharmaceuticalsobesity
Open a keyword to see other news on the same topic.
Related news
- Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A mouse study funded by the NIH found that semaglutide, made by Novo Nordisk and sold as Ozempic and Wegovy, extended the lifespan of older, healthy mice by tempering aging effects, with treated mice showing better muscle and cognitive function. The author assumes that tirzepatide, Eli Lilly's main GLP-1 drug, could show similar effects, though results in humans remain a long way off. Gallup data cited in the article show that US adult use of GLP-1 weight-loss injectables has nearly quadrupled since 2024, reaching 11% this year from 3% two years ago. J.P. Morgan expects about 25 million Americans to be on GLP-1 treatment by 2030, and Morgan Stanley forecasts the market will more than double from 2025 to 2035, to $190 billion.
- Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade?
Novo's shares have fallen more than 60% after losing GLP-1 market share to Eli Lilly, and the stock trades at 11.8x forward earnings versus an 18.6x average for healthcare stocks. The article cites clinical setbacks, including CagriSema missing a 25% mean weight-loss target and losing a head-to-head trial to Zepbound, plus a failed Phase 3 study of ziltivekimab. Second-quarter net sales rose 2% to 78.5 billion Danish kroner, and adjusted earnings per share rose 5% to 6.18 DKK. Oral Wegovy has helped widen the market, and the pipeline includes zenagamtide, which showed up to 24.3% mean weight loss over 36 weeks in an early study. The author concludes Novo is not a once-in-a-decade buy, though it could deliver solid returns over the medium term.
- Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market
Regeneron (REGN) has at least two promising weight-loss candidates in its pipeline. Olatorepatide, licensed from a China-based company, mimics the GLP-1 and GIP hormones; in a Phase 3 study in China it led to mean weight loss of up to 19% over 48 weeks, with lower gastrointestinal adverse event rates than some competing drugs, though late-stage U.S. trials are still needed. Trevogrumab is not a weight-loss drug but is designed to be used alongside anti-obesity medicines to help preserve lean mass; in a Phase 2 study with Novo's semaglutide, lean mass preservation reached up to 42.5% versus 7.3% with semaglutide plus placebo. Dupixent, an eczema medicine co-marketed with Sanofi, remains the main growth driver: Regeneron's second-quarter revenue rose 17% year over year to $4.3 billion, and Dupixent's global sales increased 38% to $6 billion. U.S. combined revenue from Eylea and Eylea HD fell 12% to $1 billion amid biosimilar competition, while HD Eylea sales reached $596 million, up 52%.
- This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock
Eli Lilly tested tirzepatide (the active ingredient in Zepbound) combined with eloralintide, an experimental drug targeting the amylin hormone rather than GLP-1. After 48 weeks, the combination produced weight loss of up to 23.3%, versus 14.8% with tirzepatide alone and 12.3% with eloralintide alone. However, discontinuation rates due to side effects reached as high as 27%, though Lilly’s Ken Custer noted that high discontinuation was also seen with tirzepatide in a mid-stage trial and that dosing can matter. The author views the results as a net positive but flags a steep valuation, with a market cap above $1 trillion and the stock trading near 40 times trailing earnings after rising around 10% this year.
- Korea 1st homegrown obesity drug likely to intensify price competition
Hanmi Pharma's Eppe, Korea's first domestically developed GLP-1-based obesity drug, was approved by the Ministry of Food and Drug Safety on Oct. 7 and is expected to intensify price competition with Mounjaro and Wegovy. Its first-month supply is projected at about 129,800 won, roughly half Mounjaro's Korean price, and it is expected to cost 17 percent less than Wegovy and 19 percent less than Mounjaro during maintenance treatment. The article notes that Mounjaro's price in China fell as much as 66 percent amid domestic GLP-1 competition, while the Korea Customs Service detected 5,030 obesity-drug smuggling cases through August, 4.2 times the year-earlier figure, as Koreans buy cheaper Mounjaro in Japan. An industry official urged patients to weigh efficacy, side effects and existing conditions, since Eppe and Mounjaro differ in mechanism and clinical evidence.
- Stock Market Today: Nasdaq Pares Loss As Yields Dive; Drug Giant Hits All-Time High (Live Coverage)
Related markets
Latest news
- Chips lead Nasdaq lower, oil tops 5-month high: AlphaCheck
Stocks were mixed on Tuesday as chip stocks gave up the previous session's rebound while oil prices climbed. Brent crude hovered near a 5-month high at $110 per barrel and WTI traded just below $100, following Houthi rebel attacks on Saudi Arabia amid the ongoing Middle East conflict. The tech sector fell, led by Nvidia (NVDA) and AMD (AMD), while memory makers Micron (MU) and SK Hynix (SKHY) also declined as Monday's rebound in the AI trade faded. Investors focused on earnings from GM, GE Aerospace and RTX released Tuesday, with SpaceX, Tesla and Meta also expected to report later in the week.
- Salesforce announces $5.66 billion deal for Braze, sending BRZE stock soaring 50%
Salesforce agreed to buy customer engagement platform Braze for about $5.66 billion, with Braze Class A holders receiving $47.50 in cash per share and closing expected in fiscal 2028, according to a Salesforce blog. Salesforce shares slipped about 1% Tuesday morning, while BRZE soared more than 50% after a brief premarket halt, from a $30.04 close on Monday. Braze makes AI marketing tools for managing customer data and messaging, and CEO Bill Magnuson said Salesforce's platform will help the company innovate faster.
- SpaceX reports after the bell. Here's what options traders expect
SpaceX reports earnings after the bell on Tuesday. Over the past three months it delivered four astronauts to the International Space Station in record time, expanded its mobile network spectrum, was reportedly eyeing a $40 billion debt deal to buy Nvidia chips, and CEO Elon Musk said he plans to give shares to every kid in America next year. Options market-makers price a roughly 6% move after the report, per Cboe LiveVol data, less than half the 13% erased after its August debut report. The stock rallied 60% over the following two months before reversing, dropping as much as 19% in the past two weeks. Monday's 1.1 million contracts traded were 20% above the 30-day average, with 665,000 calls, and implied volatility is 62 versus above 110 before second-quarter earnings. Two lockup releases, one two days after earnings and one on October 26, together cover over 1.6 billion shares, while earlier releases on Sep. 9, 10 and 24 had no discernible effect.
- Hedge Funds Dumped Tech Stocks at the Fastest Pace in a Decade, Goldman Says
Goldman Sachs prime brokerage data showed hedge funds sold technology stocks at the fastest pace in at least a decade in the week through October 15, 2026, with semiconductors taking the largest dollar hit. The selling was mainly long liquidation, meaning funds sold shares they already owned rather than opening many new short positions. The Nasdaq 100 fell 5.5% that week, its worst week since April 2025, and net leverage dropped to 48.6%, a one-year low, yet tech still made up 23.5% of Goldman's global prime book, in the 90th percentile of the past 5 years. Nvidia (NVDA) fell 4.08% over the week versus 7.88% for the iShares Semiconductor ETF (SOXX). A close below $214.13 would suggest the selling has not run its course, while a move back to $226.32, its October 12 close, would indicate funds have finished selling.
- Kazakhstan court bars Coinbase, five others from unlicensed crypto services in Astana International Financial Centre
Kazakhstan's financial regulator AFSA secured court orders restricting Coinbase and five other exchanges, including BingX, Bitcoin.com, Huobi Global (HTX), BitMart and WEEX, from offering or marketing unlicensed digital asset services in the Astana International Financial Centre (AIFC). The injunctions apply only to users within the AIFC, not nationwide, and bind Google and Apple as app-store operators, though the court declined to issue a separate injunction against them and said AFSA should first discuss necessary steps with the firms. LBank was removed from the case on Sept. 18 after addressing AFSA's concerns and blocking access in Kazakhstan. Other platforms failed to respond in time, so the court entered default judgment, and AFSA had begun warnings to more than 20 platforms in 2025.
- Gunnison Copper expands to Wall Street with NYSE American ADR listing
Gunnison Copper is listing an ADR on the NYSE American under the symbol GUNN, with trading expected on or about October 26, subject to SEC registration effectiveness and final exchange approvals. Each ADR represents 30 common shares, giving US institutional and retail investors broader access to the Phoenix-based domestic copper producer. The company produces copper cathode at its Johnson Camp Mine in Arizona, supplies the US defense sector and Amazon Web Services, and is advancing the Gunnison Copper Project about 1.5 miles away. The listing complements its existing Toronto and Frankfurt listings and does not affect its common shares.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.